Peritoneal Neoplasms: Clinical Trials

13 trials for Peritoneal Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated. 13 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Terminated 13
Phase 31Terminated 1

Follow Peritoneal Neoplasms: new trials by email Literature Review of Peritoneal Neoplasms trials Research Report on Peritoneal Neoplasms

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.
Indocyanine green - Gastric Cancer, Gastric Adenocarcinoma
Phase 2TerminatedLaval University112022-12-152024-04-02
Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis
Pasireotide 0.9 MG/ML, Saline water - Peritoneal Carcinomatosis
Phase 2TerminatedGustave Roussy, Cancer Campus, Grand Paris62020-09-032024-02-08
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter - Gastric Adenocarcinoma, Gastric Cancer
Phase 2TerminatedNational Cancer Institute (NCI)122020-06-092026-05-05
Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
Alvimopan, Placebo - Ileus
Phase 2TerminatedUniversity of California, San Diego842018-03-082021-08-18
Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study
Perioperative chemotherapy, Cytoreduction, HIPEC - Gastric Cancer, Peritoneal Carcinomatosis
Phase 2TerminatedRichard van Hillegersberg32017-08-012019-04-17
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
positive cytology with HIPEC - Gastric Cancer, Peritoneal Carcinomatosis
Phase 2 / Phase 3TerminatedUniversity Hospital Tuebingen32012-09-012018-01-30
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Birinapant (TL32711) - Epithelial Ovarian Cancer, Peritoneal Neoplasms
Phase 2TerminatedNational Cancer Institute (NCI)112012-08-152017-05-30
Combined Anticancer Treatment of Advanced Colon Cancer
CRS, HIPEC - Peritoneal Carcinomatosis, Colorectal Cancer Metastatic
Phase 2TerminatedUniversity of Regensburg262010-10-012018-09-05
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer
Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC) - Peritoneal Carcinomatosis, Gastrointestinal Cancer
Phase 2TerminatedBaki Topal342010-07-012015-12-02
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Volociximab - Ovarian Cancer, Peritoneal Neoplasms
Phase 2TerminatedFacet Biotech162007-08-012012-08-23
Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
cetuximab, fluorouracil, leucovorin calcium - Colorectal Cancer, Primary Peritoneal Cavity Cancer
Phase 2TerminatedInstitut BergoniƩ182007-05-012025-08-29
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Vandetanib - Ovarian Neoplasms, Fallopian Tube Neoplasms
Phase 2TerminatedNational Cancer Institute (NCI)122007-01-012012-06-26
A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis
Surgical debulking with peritonectomy, Intraperitoneal 5FU, FOLFOX - Peritoneal Neoplasms
Phase 2TerminatedWashington University School of Medicine182006-05-012016-12-13

Narrower conditions

Stomach Neoplasms (4)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Colorectal Neoplasms (2)  ·  Fallopian Tube Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Colonic Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Ileus (1)  ·  Neoplasms (1)  ·  Rectal Neoplasms (1)

Broader conditions

Abdominal Neoplasms (13)  ·  Digestive System Diseases (13)  ·  Digestive System Neoplasms (13)  ·  Neoplasms by Site (13)  ·  Peritoneal Diseases (13)  ·  Neoplasms (12)  ·  Gastrointestinal Diseases (8)  ·  Gastrointestinal Neoplasms (6)  ·  Stomach Diseases (4)  ·  Adnexal Diseases (3)  ·  Carcinoma (3)  ·  Endocrine Gland Neoplasms (3)  ·  Endocrine System Diseases (3)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)

Interventions

Cytoreduction Surgical Procedures (3)  ·  Hyperthermic Intraperitoneal Chemotherapy (3)  ·  Cisplatin (2)  ·  Fluorouracil (2)  ·  Leucovorin (2)  ·  Oxaliplatin (2)  ·  Capecitabine (1)  ·  Cetuximab (1)  ·  Chemotherapy, Adjuvant (1)  ·  Folfox protocol (1)  ·  Indocyanine Green (1)  ·  Paclitaxel (1)  ·  Saline Waters (1)  ·  alvimopan (1)  ·  birinapant (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Baki Topal (1)  ·  Facet Biotech (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Institut BergoniĆ© (1)  ·  Laval University (1)  ·  Richard van Hillegersberg (1)  ·  University Hospital Tuebingen (1)  ·  University of California, San Diego (1)  ·  University of Regensburg (1)  ·  Washington University School of Medicine (1)

Countries

United States (6)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Belgium (1)  ·  Netherlands (1)

Top investigators

Alexandre Brind'Amour, MD (1)  ·  Andrew Blakely, M.D. (1)  ·  Baki Topal, MD, PhD (1)  ·  C. William Helm, MD (1)  ·  Carolyn Matthews, MD (1)  ·  Christina M Annunziata, M.D. (1)  ·  Dana Glenn, MD (1)  ·  Deborah Armstrong, MD (1)  ·  Elise C Kohn, M.D. (1)  ·  Eric Winquist, MD (1)  ·  Ernst Lengyel, MD (1)  ·  James Burke, MD (1)  ·  James Fleshman, M.D. (1)  ·  Jelle P Ruurda, MD PhD (1)

Results publications

PMID 20068097, PMID 27520560, PMID 29149865, PMID 30131226, PMID 31331370, PMID 36102565

NIH funding

2009 (1), 2016 (1), 2019 (1)